The Fibrolamellar Cancer Foundation
Fibrolamellar Cancer Foundation,(the "foundation") was established to raise awareness and research funds for fibrolamellar carcinoma, a rare form of liver cancer that is primarily seen in teens and young adults. Currently, there are no viable treatment options other than liver resection surgery. Our mission is to find a cure and reliable treatment options for those diagnosed with this rare disease as well as enhance communications among healthcare professionals and patients.
The Fibrolamellar Cancer Foundation at a glance
In short: The Fibrolamellar Cancer Foundation gave $1.4M across 7 grants in 2024 (avg $200K), mostly in Massachusetts. Source: 2024 IRS Form 990.
- Annual giving (2024)
- $1,402,248
- -65.6% vs 2023
- Grants made (2024)
- 7
- -36.4% vs 2023
- Average grant
- $200,321
- -45.9% vs 2023
- Median grant
- $199,996
- Total assets
- $10,229,754
- -2.6% vs 2023
- Primary geography
- Massachusetts (67% of itemized 2024 grant dollars)
- Latest 990 filing
- Form 990, 2024 View filing
Data from IRS Form 990, 2024; updated September 2026.
How to apply to The Fibrolamellar Cancer Foundation
Open Grants
1 open opportunity from The Fibrolamellar Cancer Foundation
Who The Fibrolamellar Cancer Foundation funds
How this funder distributes its grants
Top Recipients
Top 7 recipients in 2024
The largest 2024 recipient was X-Chem Inc ($400K). Together the top 7 received $1.4M.
Grant Size Distribution
41 grants across all recorded years
The most common grant size was in the $100–250K range: 14 grants of 41 (34%).
Geographic Focus
Where this funder awards grants
Grant Distribution by State
Share of 2024 grant dollars across all 7 itemized grants.
Cities
How The Fibrolamellar Cancer Foundation gives
- Giving grew 74% from 2021 to 2024. Method
From the foundation's IRS Form 990 filings. Methodology.
Giving History
Giving Over Time
Total grant dollars and number of grants per year
From 2020 to 2024, annual grant giving ranged from $804K (2021) to $4.1M (2023). In 2024 it made 7 grants totaling $1.4M.
Grants by year
Grant recipients and amounts by year
| Recipient | Purpose | Amount |
|---|---|---|
| X-Chem Inc Waltham, MA | Scientific Research | $400,000 |
| Seven Bridges Genomics Inc Charlestown, MA | Scientific Research | $324,000 |
| University of Washington Seattle, WA | Scientific Research | $200,000 |
| Massachusetts General Hospital Cancer Center Boston, MA | Scientific Research | $199,996 |
| University of Wisconsin Madison, MI | Scientific Research | $138,212 |
| Fred Hutchinson Cancer Center Seattle, WA | Scientific Research | $125,000 |
| Dana-Farber Cancer Institute Boston, MA | Scientific Research | $15,040 |
Ready to take the next step with The Fibrolamellar Cancer Foundation?
Financial History
Multi-year comparison from IRS filings
| Filing year | Total Assets | Revenue | Expenses | Grants paid | Grants | Net Investment Income |
|---|---|---|---|---|---|---|
| 2024 | $10,229,754 | $3,413,883 | $2,853,234 | $1,402,248 | 7 | $325,349 |
| 2023 | $10,499,605 | $2,960,135 | $5,485,040 | $4,073,954 | 11 | $719,035 |
| 2022 | $10,981,422 | $6,076,635 | $2,563,688 | $1,373,548 | 8 | $3,055 |
| 2021 | $7,664,472 | $4,041,093 | $1,865,036 | $804,000 | 6 | $14,468 |
| 2020 | $5,395,682 | $1,841,395 | $2,741,615 | $1,930,966 | 9 | $2,942 |
About The Fibrolamellar Cancer Foundation
Based on IRS filings
The Fibrolamellar Cancer Foundation is a public charity focused on Diseases, Disorders & Medical Disciplines, based in Greenwich, CT. IRS filing data is available from 2020 through 2024. As of 2024, the organization holds $10.2M in total assets. In 2024, it awarded 7 grants totaling $1.4M. Net investment income was $325K.
Focus Areas
Leadership & Key People
Officers and directors from IRS filings
The Fibrolamellar Cancer Foundation is led by Kurt Losert, CEO on every filing since 2022; 3 of 13 officers listed in 2024 are compensated.
Officers on the 2024 filing
Kurt Losert
CEO
On filings since 2022
40 hrs/week
$273K (2023) → $251K (2024)
Charles A. Davis
Co-Chairperson
Director → Co-Chairperson, 2022
On filings since 2020
1 hr/week
No compensation reported
Marna O. Davis
Co-Chairperson
Chairperson → Co-Chairperson, 2022
On filings since 2020
25 hrs/week
No compensation reported
Payal Ray
Program Research Director
New on the 2024 filing
40 hrs/week
$154K (2024)
Anne Adler
Director
On filings since 2020
25 hrs/week
No compensation reported
Charles W. Beermann
Director
On filings since 2020
1 hr/week
No compensation reported
Craig Martin
Director
On filings since 2020
1 hr/week
No compensation reported
Derek Gilchrist
Director & Secretary
On filings since 2020
2 hrs/week
No compensation reported
John Craig
Director
On filings since 2020
1 hr/week
No compensation reported
Tal Friedman
Director
On filings since 2020
1 hr/week
No compensation reported
Guy Levy
Director
On filings since 2023
1 hr/week
No compensation reported
Mark Furth
Chief Science Officer
Director → Scientific Director, 2022
Scientific Director → Chief Science Officer, 2024
On filings since 2020
40 hrs/week
$157K (2020) → $165K (2024)
Leslie Graves
Treasurer
On filings since 2020
1 hr/week
No compensation reported
Former officers (3)
- Former: David J. Wermuth (2020–2023) — Director
- Former: John Hopper (2020–2023) — Director
- Former: Alisha Sternenberger (2020–2021) — Director
Data from IRS Form 990 filings, 2020–2024. "On filings since" is the earliest filing we hold that lists the person; hours are average hours per week as reported.
Compensation Overview
From 2024 IRS filing
The highest reported compensation on the 2024 filing was $251K, to Kurt Losert (CEO). 3 officers or directors reported compensation on that filing.
Frequently asked questions about The Fibrolamellar Cancer Foundation
How much does The Fibrolamellar Cancer Foundation give each year?
The Fibrolamellar Cancer Foundation gave $1.4M across 7 grants in 2024, according to its 2024 IRS Form 990. In 2023 it gave $4.1M across 11 grants.
What is The Fibrolamellar Cancer Foundation's typical grant size?
The Fibrolamellar Cancer Foundation's median grant in 2024 was $199,996, and its average grant was $200,321, across 7 grants on its 2024 IRS Form 990.
Where does The Fibrolamellar Cancer Foundation give grants?
The Fibrolamellar Cancer Foundation gives mostly in Massachusetts: 67% of the grant dollars itemized on its 2024 IRS Form 990 went to recipients there. The next largest states were Washington (23%) and Michigan (10%). The most frequent recipient cities were Seattle, WA (2 grants) and Boston, MA (2 grants).
Does The Fibrolamellar Cancer Foundation give general operating support?
Not in 2024: none of the 7 grants with a stated purpose on The Fibrolamellar Cancer Foundation's 2024 IRS Form 990 were described as general or operating support. Recurring purposes include "Scientific Research" (7 grants).
Who are The Fibrolamellar Cancer Foundation's largest grantees?
The Fibrolamellar Cancer Foundation's largest 2024 grantees include X-Chem Inc ($400,000), Seven Bridges Genomics Inc ($324,000) and University of Washington ($200,000), according to its 2024 IRS Form 990. Together they received 66% of its itemized 2024 grant dollars.
How large is The Fibrolamellar Cancer Foundation?
The Fibrolamellar Cancer Foundation reported $10.2M in total assets on its 2024 IRS Form 990. Its revenue that year was $3.4M.
What is The Fibrolamellar Cancer Foundation?
The Fibrolamellar Cancer Foundation is a public charity focused on Diseases, Disorders & Medical Disciplines, based in Greenwich, CT. It holds $10.2M in total assets as of 2024.
What is The Fibrolamellar Cancer Foundation's EIN?
The Fibrolamellar Cancer Foundation's EIN (Employer Identification Number) is 27-0341021. IRS Form 990 filing data is available on this page for 2020–2024.
Data last updated September 2026. Sourced from IRS Form 990 filings.
Data update history
(6)
When this profile's IRS filing data changed on Grantable
- Updated Form 990 for fiscal year 2020 (received by the IRS November 15, 2021)
- Updated Form 990 for fiscal year 2021 (received by the IRS November 15, 2022)
- Updated Form 990 for fiscal year 2022 (received by the IRS November 14, 2023)
- Updated Form 990 for fiscal year 2023 (received by the IRS November 15, 2024)
- Updated Form 990 for fiscal year 2024 (received by the IRS November 16, 2025)
- IRS filings on file for fiscal years 2020–2024
Explore Open Grants
Browse active grant opportunities in The Fibrolamellar Cancer Foundation's focus areas in our free grants database
Similar Funders
Funders that support many of the same organizations
Enterprise Holdings Foundation
Saint Louis, MO
The Enterprise Holdings Foundation supports charitable and educational nonprofits in communities where Enterprise Mobility operates, focusing on health, education, arts, and disaster relief; applicants must be actively supported by an Enterprise Mobility team member, spouse, or domestic partner. Giving varies widely: it reported 9,499 grants in 2024, but its 2025 filing showed one grant of $101.4 million, so that amount is not a typical award. Applications are accepted at any time through eligible Enterprise-affiliated applicants; the Foundation does not limit giving to preselected organizations.
Assets
$594.3M
Grants
1
Total Given
$101.4M
Children's Cancer Research Fund
Minneapolis, MN
Children’s Cancer Research Fund supports childhood cancer research, training, and programs for children and families, including survivorship and bereavement services. Its 2025 grants ranged from $25,000 to $1.575 million, with a median of $250,000; it funds research nationwide, though most 2025 grant dollars went to Minnesota. Its Emerging Scientist Awards are open, but the profile does not state whether CCRF accepts unsolicited requests generally.
Assets
$11.2M
Grants
7
Total Given
$3.0M
Citizens United for Research in Epilepsy
Chicago, IL
Citizens United for Research in Epilepsy funds high-risk, high-reward research aimed at advancing a cure, including basic, pediatric, treatment-resistant, and rare epilepsy research. Recent grants had a median of about $100,000, with awards ranging from $6,300 to $258,324; funding reaches researchers in the U.S. and internationally. The available materials describe an application process for specific awards but do not state whether unsolicited requests are accepted.
Assets
$10.4M
Grants
14
Total Given
$1.3M
Conquer Cancer Foundation of the American Society of Clinical Oncology
Alexandria, VA
Conquer Cancer funds cancer research, professional education, and quality-care initiatives, with awards to universities, hospitals, and cancer centers in the U.S. and through international programs. Its 2024 grants ranged from $50,000 to $7.68 million, with a median of $100,000; the profile does not state whether it accepts unsolicited requests.
Assets
$120.7M
Grants
39
Total Given
$17.4M
Blood Cancer United Inc
Washington, DC
Blood Cancer United funds blood cancer research, including basic, translational, and clinical studies, along with patient and family support, quality-of-life work, and advocacy. Its 2025 grants ranged from $37,500 to $5,197,687, with a median of $370,000; funding supports work in the U.S. and internationally. The profile does not state whether it accepts unsolicited requests.
Assets
$532.2M
Grants
67
Total Given
$47.7M
Edward P Evans Foundation
Charlestown, MA
The Edward P. Evans Foundation primarily funds collaborative medical research on MDS and AML, with additional support for educational-institution capital projects and modern American visual arts. Its 2025 grants ranged from $25,000 to $1,602,500, with a median of $200,000, and went to organizations in multiple states. It does not accept unsolicited requests and gives only to preselected charitable organizations.
Assets
$260.6M
Grants
44
Total Given
$14.2M
More similar funders
More Funders in Connecticut
The filing figures on this page are open data under CC BY 4.0. About GrantGraph Open
Figures come from The Fibrolamellar Cancer Foundation's IRS filings (methodology). AI-written summaries, news items and logos are not covered by the open licence. Spot an error? Email hello@grantable.co.
The Fibrolamellar Cancer Foundation down — hundreds of funders to go?